Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Enanta Pharmaceuticals, Inc. (ENTA : NSDQ)

• Company Description    Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. Number of Employees: 120

• Price / Volume Information    Yesterday's Closing Price: $14.73 Daily Weekly Monthly 20 Day Moving Average: 295,728 shares Shares Outstanding: 28.86 (millions) Market Capitalization: $425.15 (millions) Beta: 0.96 52 Week High: $15.34 52 Week Low: $4.09 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 25.68% 24.03% 12 Week 87.88% 82.50% Year To Date 156.17% 109.59%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4 KINGSBURY AVENUE - WATERTOWN,MA 02472 USA ph: 617-607-0800 fax: 617-607-0530 ir@enanta.com http://www.enanta.com

• General Corporate Information    Officers Jay R. Luly - President and Chief Executive Officer and Director Harry R. Trout - Vice President; Finance Bruce L.A. Carter - Director Mark G. Foletta - Director Yujiro S. Hata - Director Peer Information Enanta Pharmaceuticals, Inc. (CORR.) Enanta Pharmaceuticals, Inc. (RSPI) Enanta Pharmaceuticals, Inc. (CGXP) Enanta Pharmaceuticals, Inc. (BGEN) Enanta Pharmaceuticals, Inc. (GTBP) Enanta Pharmaceuticals, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 29251M106 SIC: 2834 Fiscal Year Fiscal Year End: September Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/09/26 Share - Related Items Shares Outstanding: 28.86 Most Recent Split Date: (:1) Beta: 0.96 Market Capitalization: $425.15 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.54 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.30 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/09/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.87 Price/Cash Flow: - Price / Sales: 6.51 EPS Growth vs. Year Ago Period: 36.03% vs. Previous Quarter: -2.35% Sales Growth vs. Year Ago Period: 3.55% vs. Previous Quarter: -17.41% ROE 09/30/25 - -93.76 06/30/25 - -89.02 03/31/25 - -79.83 ROA 09/30/25 - -26.13 06/30/25 - -27.28 03/31/25 - -26.65 Current Ratio 09/30/25 - 4.21 06/30/25 - 5.00 03/31/25 - 5.29 Quick Ratio 09/30/25 - 4.21 06/30/25 - 5.00 03/31/25 - 5.29 Operating Margin 09/30/25 - -125.36 06/30/25 - -141.98 03/31/25 - -149.57 Net Margin 09/30/25 - -125.36 06/30/25 - -141.98 03/31/25 - -149.57 Pre-Tax Margin 09/30/25 - -127.90 06/30/25 - -145.15 03/31/25 - -153.41 Book Value 09/30/25 - 3.03 06/30/25 - 3.71 03/31/25 - 4.38 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 1.99 06/30/25 - 1.67 03/31/25 - 1.42

Powered by Zacks Investment Research ©